Metabolic control in type 2 diabetes is associated with sulfonylurea receptor-1 (SUR-1) but not with KCNJ11 polymorphisms by Nikolac, Nora et al.
 1 
 
 
    
 
Središnja medicinska knjižnica 
 
 
 
 
Nikolac N., Šimundić A.M., Katalinić D., Topić E., Čipak A., Zjačić-
Rotkvić V. (2009) Metabolic control in type 2 diabetes is associated 
with sulfonylurea receptor-1 (SUR-1) but not with KCNJ11 
polymorphisms.  Archives of Medical Research, 40 (5). pp. 387-392. 
ISSN 0188-4409 
 
 
http://www.elsevier.com/locate/issn/01884409 
 
http://www.sciencedirect.com/science/journal/01884409 
 
http://dx.doi.org/10.1016/j.arcmed.2009.06.006 
 
 
 
 
http://medlib.mef.hr/682 
 
 
University of Zagreb Medical School Repository 
http://medlib.mef.hr/ 
   
 
 
 
 
 2 
Metabolic control in type 2 diabetes is associated with sulfonylurea receptor-1 (SUR-1) but 
not with KCNJ11 polymorphisms 
 
Running title: SUR-1 and KCNJ11 polymorphisms and type 2 diabetes 
 
Nora Nikolac1*, Ana-Maria Simundic1, Darko Katalinic2, Elizabeta Topic1, Andrea Cipak1, 
Vanja Zjacic Rotkvic2 
 
1University Department of Chemistry, Sestre Milosrdnice University Hospital, Zagreb, 
Croatia 
2Division of Endocrinology and Metabolic Diseases, Department of Medicine, Sestre 
Milosrdnice University Hospital, Zagreb, Croatia 
 
 
*Corresponding author: 
Nora Nikolac 
University Department of Chemistry 
Sestre Milosrdnice University Hospital 
Vinogradska 29 
10000 Zagreb 
Croatia 
Phone/fax: +385 1 3768 280 
e-mail: nora.nikolac@gmail.com 
 
 3 
Abstract 
 
Background: The sulfonylureas are hypoglycemic agents used for promotion of insulin 
secretion in type 2 diabetics. They bind to sulfonylurea receptor-1 (SUR-1), which is a 
functional subunit of the ATP-sensitive potassium channel (KATP). The other component of 
potassium channel is Kir6.2, encoded by gene KCNJ11. Polymorphisms in these genes may 
lead to modulated response to sulfonylurea therapy. 
 
Aim: Aim of this study was to determine a relationship between SUR-1 [exon 16 (-3C/T), 
exon 31 (Arg1273Arg; AGG→AGA) and exon 33 (S1369A)] and KCNJ11 (E23K) 
polymorphisms and following parameters of metabolic control in type 2 diabetes: fasting 
plasma glucose (FPG), postprandial glucose (PPG) and HbA1c in Caucasian type 2 diabetics 
of the European origin. 
 
Methods: A total of 228 unrelated patients with type 2 diabetes on sulfonylurea therapy were 
included in the study. Genotyping of all polymorphisms was performed by PCR-RFLP 
method; biochemical parameters were determined using standard laboratory methods.  
 
Results: There was no difference in FPG and PPG concentration in any of the genotype 
subgroups. However, diabetics with wild type C/C genotype of the SUR-1 exon 16 
polymorphism had significantly lower HbA1c concentration compared to the patients with 
variant T/T genotype [6.9 (6.2-7.7) mmol/L vs. 8.1 (6.7-8.8) mmol/L; p = 0.009]. Also, 
patients with wild type G/G genotype of the SUR-1 exon 31 polymorphism had significantly 
higher HbA1c concentration compared to the patients with variant A/A genotype [7.8 (6.9-
8.8) mmol/L vs. 6.3 (5.7-6.8) mmol/L; p < 0.001]. 
 
Conclusion: SUR-1 exon 16 and exon 31 polymorphisms are significantly associated with 
HbA1c concentration. 
 
Keywords: diabetes mellitus type 2; genetic polymorphism; glucose concentration; HbA1c; 
sulfonylurea receptor-1  
 
 4 
Introduction 
 
The sulfonylureas are hypoglycemic agents used for promotion of insulin secretion in type 2 
diabetics (1). They bind to sulfonylurea receptor-1 (SUR-1), which is a functional subunit of 
the ATP-sensitive potassium channel (KATP) located in pancreatic beta cells in islets of 
Langerhans. The other component of potassium channel is Kir6.2, inwardly rectifying ion 
channel forming a pore, encoded by gene KCNJ11. Mechanism of action of sulfonylureas 
includes binding to SUR-1 subunit of potassium channel causing its closure, opening of 
voltage-gated Ca2+ channels, increase of intracellular Ca2+ concentration and stimulation of 
insulin release from secretory granules by exocytosis. Closure of KATP is not initiated only by 
sulfonylurea action, but also by ATP production in glucose metabolism, indicated significant 
role of SUR-1 and Kir6.2, not only in diabetics under sulfonylurea therapy, but in diabetes in 
general (2,3,4). 
The genes encoding SUR-1 and Kir6.2 are located on the chromosome 11p15.1. Numerous 
polymorphisms of these genes are reported in association with susceptibility to type 2 
diabetes and diabetic phenotypes (5,6,7). These polymorphisms may lead to a loss of activity 
of potassium channel and to uncontrolled over secretion of insulin (2), as well as modulated 
response to sulfonylurea therapy (8,9).  
In this study we have investigated three polymorphisms of SUR-1 gene [polymorphism in 
intron 15 splice acceptor site (exon 16 -3C/T); silent polymorphism in exon 31 (Arg1273Arg; 
AGG→AGA) and missense polymorphism in exon 33 (S1369A)] and as well as missense 
polymorphism KCNJ11 gene (E23K).  
The aim of this study in type 2 diabetics on sulfonylurea therapy was to determine the 
relationship between SUR-1 and KCNJ11 polymorphisms and following parameters of 
metabolic control: i) fasting plasma glucose (FPG), ii) postprandial glucose (PPG) and iii) 
HbA1c concentration.  
 
Materials and Methods 
 
Subjects 
Total of 228 unrelated patients with type 2 diabetes on sulfonylurea therapy were 
prospectively recruited during their regular quarterly chek-up at the Division of 
Endocrinology and Metabolic Diseases, Sestre Milosrdnice University Hospital in Zagreb, 
 5 
from January to June 2007. All patients were Caucasians of the European origin. Exclusion 
criteria were: any therapeutic or lifestyle modification within the last year or any recent acute 
diabetic complication. Height and weight were measured for BMI calculation. Diagnosis of 
diabetes was made according to WHO criteria from 2006.  
All patients complied with physician’s recommendations regarding therapy and diet and 
signed informed consent for participating in the study. The study protocol was approved by 
the Ethical Committee of the Hospital. 
 
Biochemical parameters 
Samples for FPG and HbA1c determination were collected after overnight fast. Sodium 
Fluoride/Potassium Oxalate plasma was used for glucose measurement (FPG and PPG), 
whole blood with K3EDTA for both, genotyping and HbA1c determination and serum for 
lipid concentration measurement (BD Vacutainer®, Franklin Lakes, NJ, USA).  
Immediately after venipuncture, patients had a standard continental breakfast (4-5 ADA 
units). Sample for PPG measurement was collected two hours after the meal.  
All analyses were performed immediately after the blood collection. Biochemical parameters 
were determined on automatic analyzer Olympus AU 2700, using original manufacturer’s 
reagents for glucose, triglycerides, total, HDL and LDL cholesterol (Olympus, Hamburg, 
Germany) and Pointe Scientific, Inc reagent for HbA1c measurement (Canton, MI, USA).  
 
Genotyping 
Genomic DNA was extracted from peripheral blood leukocytes using commercially available 
QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). All polymorphisms were detected 
by PCR-RFLP method according to previously published protocols (5,10,11) with some 
modifications of PCR amplifying conditions and primer sequence. Genotyping conditions are 
described in Table 1. 10% of total samples were double-genotyped. Double-genotyping did 
not reveal any discrepancies in the result. One negative control was used per every 20 
samples.  
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Table 1. Genotyping conditions 
 Forward and reverse primers Restricti
on 
enzyme 
Restriction 
pattern (bp) 
SUR1 exon 16 
(-3C/T) 
5-GCATCTGTCTGTCTGTCTTTCTGGG-3 
5-GGAGCGAGGACTTGCCGC-3 
HpyCH4 
V 
C: 80 + 54 
T: 134 
SUR1 exon 31 
(Arg1273Arg) 
5-GTAGAACAGGGTCCTGTGGC-3 
5-TGTCTCCAGTGACGAAGGTG-3 
Bsl I G: 132 + 65 + 
52 + 1 
A: 198 + 52 
SUR1 exon 33 
(S1369A) 
5-AGGGAGAGGGGTGGGAAGAGTCCAA-3 
5-ATTGGGTTGGGCCCGTGCACTGAC-3 
Mwo I T: 206 + 82  
G: 206 + 41 
KCNJ11 
(E23K) 
5-GACTCTGCAGTGAGGCCCTA-3 
5-ACGTTGCAGTTGCCTTTCTT-3 
Ban II E: 150 + 32 + 
28  
K: 178 + 32  
bp – base pairs 
Statistical analysis 
Normality of distributions for quantitative variables (age and biochemical parameters) was 
tested using Kolmogorov-Smirnov test. Normally distributed variables were presented as 
mean ± standard deviation, and those that were not distributed normally with median and 
interquartile range. 
Genotype frequencies were calculated by direct counting. Difference between observed and 
expected genotype frequencies for calculating Hardy-Weinberg equilibrium was tested using 
Chi-square test.  
Linkage disequilibrium analysis was done using Linkage Disequilibrium Analyzer 1.0 
(Chinese National Humane Genome Center, Beijing, China).Overall differences in FPG, PPG 
and HbA1c concentrations according to genotype subgroups were tested by Kruskal-Wallis 
test. Dunn's method was used for post hoc testing between genotype subgroups. 
P values < 0.05 were considered statistically significant. Statistical analysis was done using 
MedCalc® statistical software (MedCalc 9.3.9.0, Frank Schoonjans, Mariakerke, Belgium). 
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Results 
Characteristics of study population are presented in Table 2. Both genders were represented 
equally, whereas most of the patients were obese. Only approximately one third of the 
patients had FPG and HbA1c concentrations below ADA and WHO recommended values of 
7 mmol/L and 7%, respectively (12).  
 
Table 2. Patient’s characteristics  
Characteristics Patients 
n = 228 
Age (years) 66 ± 10 
Duration of diabetes (years) 9 (5-13) 
Age at onset of diabetes (years) 56 ± 10 
Duration of sulfonylurea therapy (years) 7 (4-12) 
Male gender (n, %) 104 (45.6%) 
BMI (kg/m2)  29.74 ± 5.00 
FPG (mmol/L)  8.3 (7.1-10.1) 
PPG (mmol/L)  10.4 (8.0-13.2) 
HbA1c (%)  7.7 ± 1.5 
Triglycerides (mmol/L) 2.09 (1.38-2.70) 
Total cholesterol (mmol/L) 5.4 ± 1.1 
HDL cholesterol (mmol/L) 1.30 (1.10-1.50) 
LDL cholesterol (mmol/L) 3.1 ± 1.0 
 
Data are presented with mean ± standard deviation or median and interquartile range.  
FPF – fasting plasma glucose; PPG – postprandial glucose  
Overall distribution of polymorphisms is shown in Table 3. Genotype frequencies for all 
tested polymorphisms were in Hardy-Weinberg equilibrium.  
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Table 3. Overall distribution of polymorphisms 
Polymorphism Genotype/Allele Total n = 228 
n, % 
p* 
C/C 45 (19.7) 
C/T 133 (58.3) 
T/T 50 (22.0) 
0.186 
C 223 (48.9)  
SUR-1 exon 
16 (-3C/T) 
T 233 (51.1)  
G/G 136 (59.6) 
G/A 82 (36.0) 
A/A 10 (4.4) 
0.949 
G 354 (77.6)  
SUR-1 exon 
31 
(Arg1273Arg) 
A 102 (22.4)  
T/T 90 (39.5) 
T/G 97 (42.5) 
G/G 41 (18.0) 
0.502 
T 277 (60.7)  
SUR-1 exon 
33 (S1369A) 
G 179 (39.3)  
E/E 87 (38.3) 
E/K 103 (45.2) 
K/K 38 (16.7) 
0.842 
E 277 (60.7)  
KCNJ11 
(E23K) 
K 179 (39.3)  
p* for Hardy-Weinberg equilibrium, Chi-square test 
SUR-1 exon 33 (S1369A) and KCNJ11 (E23K) polymorphisms were in strong linkage (R2 = 
0.9278). Linkage disequilibrium was not observed for any other polymorphism pair. 
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Therefore, only results for the E23K polymorphism are presented in the rest of this 
manuscript. 
Differences in FPG, PPG and HbA1c concentrations in patient subgroups according to 
genotypes are shown in Table 4. There were no differences in FPG and PPG concentration in 
neither of genotype subgroups. However, HbA1c concentration differed significantly across 
SUR-1 exon 16 (-3C/T) and SUR-1 exon 31 (Arg1273Arg) genotype subgroups. Diabetics 
with wild type C/C genotype of the SUR-1 exon 16 polymorphism had significantly lower 
HbA1c concentration compared to the patients with variant T/T genotype [6.9 (6.2-7.7) 
mmol/L vs. 8.1 (6.7-8.8) mmol/L; p = 0.009]. Results were quite opposite for the SUR-1 exon 
31 polymorphism: patients with wild type G/G genotype had significantly higher HbA1c 
concentration compared to the patients with variant A/A genotype [7.8 (6.9-8.8) mmol/L vs. 
6.3 (5.7-6.8) mmol/L; p < 0.001]. 
 
Table 4. Differences in FPG, PPG and HbA1c concentrations in subgroups of patients 
according to genotypes of SUR-1 and KCNJ11 genes 
 FPG (mmol/L) PPG (mmol/L) HbA1c (%) 
SUR-1 exon 16 (-3C/T)  
C/C (n = 45) 8.3 (7.0-9.5) 10.2 (7.2-13.0) 6.9 (6.2-7.7) 
C/T (n = 133) 8.2 (7.0-10.3) 10.2 (8.1-14.3) 7.6 (6.7-8.6) 
T/T (n = 50) 8.4 (7.1-10.3) 10.5 (8.5-12.9) 8.1 (6.7-8.8) 
p* 0.909 0.577 0.009 
SUR-1 exon 31 (Arg1273Arg) 
G/G (n = 136) 8.4 (7.2-10.0) 10.4 (7.8-12.8) 7.8 (6.9-8.8) 
G/A (n = 82) 8.3 (7.0-10.5) 10.7 (8.2-15.1) 7.1 (6.2-8.5) 
A/A (n = 10) 7.6 (6.8-8.2) 9.5 (8.7-9.8) 6.3 (5.7-6.8) 
p* 0.630 0.474 < 0.001 
KCNJ11 (E23K) 
E/E (n = 87) 8.6 (7.2-10.4) 10.7 (8.1-14.0) 7.6 (6.4-8.5) 
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 FPG (mmol/L) PPG (mmol/L) HbA1c (%) 
E/K (n = 103) 8.3 (7.0-9.8) 10.4 (7.6-13.0) 7.5 (6.5-9.0) 
K/K (n = 38) 7.6 (6.9-9.7) 10.0 (8.0-11.6) 7.5 (6.8-8.3) 
p* 0.143 0.675 0.824 
 
Data are presented with median and interquartile range. p* - Kruskal-Wallis test.  
FPF – fasting plasma glucose; PPG – postprandial glucose. 
 
 
In order to further explore the effect of combined genotypes of SUR-1 exon 16 and exon 31 
polymorphisms, haplotype analysis was performed. All of the 9 possible combinations were 
observed. We have divided our population into two groups: those with risk alleles, i.e. 
genotypes associated with poor metabolic control of HbA1c (TT/GG, TT/GA and TC/GG; 
genotypes for exon 16 and exon 31 polymorphisms, respectively; n = 129) and those with 
genotypes associated with lover HbA1c concentration (remaining six diplotypes; n = 99). 
Patients with risk alleles (genotypes) had significantly increased HbA1c concentration 
compared to the other group (8.0 ± 1.4% vs. 7.3 ± 1.5%; p < 0.001), while no difference in 
FPG and PPG concentration was observed.  
 
Discussion 
In our study we aimed to determine the association of SUR-1 and KCNJ11 polymorphisms 
with different parameters related to short-term metabolic control of type 2 diabetes. While we 
found no evidence for the association of FBG and PPG with any of the studied 
polymorphisms, HbA1c concentration was significantly associated with SUR-1 
polymorphisms in exons 16 and 31. 
Our results have confirmed previously described linkage disequilibrium between KCNJ11 
E23K and SUR-1 exon 33 (S1369A) polymorphisms (13). All except eight of our study 
patients had identical genotypes: wild type alleles co-occurred together at both loci (same for 
the variant alleles). Hence, the concentrations of biochemical parameters across genotype 
subgroups were practically identical. We have presented our results only for the KCNJ11 
E23K genotype subgroup. 
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Literature reports on the association of SUR-1 and KCNJ11 gene variants with type 2 diabetes 
susceptibility, as well as diabetic parameters, are controversial.  
Gene variant in intron/exon boundary (SUR-1 exon 16 (-3C/T)) has been widely studied. We 
have found variant T/T genotype of the exon 16 polymorphism to be associated with 
significant elevation of HbA1c concentration in patients on sulfonylurea therapy. In a French 
study by Mierhaege et al. patients on sulfonylurea therapy with at least one wild type allele 
(C/C and C/T genotypes) had significantly (35%) lower triglyceride concentration than the 
patients with the variant T/T genotype (14). This finding, similar to our results, indicates 
adverse association of the polymorphic variant with sulfonylurea therapy efficacy. 
Several studies found association of this polymorphism and diabetes. One of the initial 
studies found this variant to be associated with diabetes in Caucasians (6). Similarly, in the 
study of Hart et al. on Dutch Caucasians, variant allele of the exon 16 polymorphism was 
more frequent in patients with diabetes compared to the healthy controls (15).  
However, there are numerous publications that have yielded negative results. In study of 
Gloyn et al. authors have investigated exon 16 polymorphism distribution in subgroups of 
patients with mild and severe diabetes, according to FPG and BMI. They did not find any 
difference in frequency distribution among these subgroups (16). Also, Polish investigators 
failed to confirm association of this polymorphism with early failure of sulfonylurea therapy 
compared to patients treated with sulfonylurea despite long diabetes duration (17). Moreover, 
a large scale association study on 854 patients with type 2 diabetes and 1182 control subjects 
found no association of exon 16 -3C/T polymorphism with type 2 diabetes (OR = 1.05 (0.91-
1.18); p = 0.57) (18). 
Though being a silent nucleotide change, exon 31 (Arg1273Arg; AGG→AGA) 
polymorphism appears to be associated with diabetic phenotypes. In our study this variant 
was also associated with HbA1c concentration. Patients with variant A/A genotype had the 
lowest, with heterozygous G/A medium and with wild type G/G genotype the highest HbA1c 
concentration. This result is opposite to our finding on exon 16 polymorphism, since in this 
case, variant allele seems to have a decreasing effect on HbA1c concentration. Results of 
other literature reports on exon 31 polymorphism and diabetes are also very variable. In a 
French study by Reis FA. et al. variant A allele was more frequent in type 2 diabetics than in 
control subjects (OR = 1.54 (1.14-2.11)) (11). Authors have also investigated differences in 
phenotypic traits in carriers of different genotypes of exon 31 polymorphism. Though they 
have found A allele to be a risk factor for diabetes development, they have found that the 
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prevalence of hypertension was much higher in the wild type allele carriers (G/G) than in the 
carriers of the variant A/A genotype in obese subjects.  
In a study on non-diabetic Mexican subjects, there was no difference in FPG and BMI across 
different genotypes, although subjects with A/A genotype had highest fasting insulin values, 
2-h insulin and proinsulin to insulin ratio (19).  
The exact molecular mechanism of the association of this gene variant with metabolic 
parameters associated with diabetes is not clear, since this silent genetic change doesn’t imply 
the change in amminoacid sequence. It is possible that this polymorphism is in linkage 
disequilibrium with some other gene variant not tested in our study, which might, in some 
way, be associated with channel structure modification. 
Recently, a mechanism of action of E23K polymorphism of the KCNJ11 gene on diabetes 
development has been proposed. E23K sensitizes pancreatic KATP channels toward activatory 
nucleoside diphosphates, while inhibitory effect of ATP is reduced. This leads to over 
activity of KATP channels in the pancreatic beta cells and inhibition of insulin release, 
predisposing to diabetes development (20,21).  
Though some literature findings support a promising role of E23K polymorphism in diabetes 
susceptibility and metabolic control, we have found no evidence that this polymorphism is 
associated with short-term diabetes outcome indicators.  
Barosso et al. (22) have performed a large candidate gene association study on type 2 
diabetes investigating 152 SNPs in 71 genes, including KCNJ11 and SUR-1 genes, among 
others. They have investigated type 2 diabetes susceptibility on 517 diabetics with matched 
control subjects and association with diabetic phenotypes on another population of 1,100 
Caucasians with type 2 diabetes. They have found E23K KCNJ11 polymorphism to be 
associated with diabetes with OR = 1.49; p = 0.033; though some other polymorphisms of 
this gene (3p+215, A190) showed protective influence on diabetes development (OR = 0.59 
and 0.62, respectfully). This variant was also tightly linked to disease status.  
In a previously mentioned paper by Gloyn AL. et al. (16), homozygous K/K genotype was 
more frequent in type 2 diabetics than in control subjects (18% vs. 9%; p = 0.007). No 
association with response to sulfonylurea therapy or with fasting plasma glucose 
concentration was observed. The same group of authors, few years later, performed a large 
meta-analysis on approximately 2,500 patients (18). The effect of E23K polymorphism on 
diabetes susceptibility was confirmed (OR = 1.23 (1.12-1.36)). Similar findings were 
replicated on several other meta-analysis by Florez (OR = 1.17; p = 0.003) (14) and Nielsen 
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(OR = 1.49; p < 0,001) (23). Interestingly, similarly like in the work of Gloyn et al., this later 
study also failed to associate E23K polymorphism with FPG (23). 
Our research has some limitations that need to be emphasized. Though the mechanism of 
action of SUR-1 and Kir6.2 involves insulin pathways, due to the technical reasons, we were 
not able to obtain data on insulin levels. The association of selected polymorphisms and 
insulin level as significant factor in diabetes control needs to be further studied. Moreover, 
since the duration of sulfonylurea therapy was not the same for all studied patients, it could 
have also influenced metabolic control of diabetes. 
Also, we did not examine other possible contributors of FPG, PPG and HbA1c such as diet, 
physical activity, comorbidity (hypertension, dyslipidemia). It is though possible that some of 
the studied relationships are influenced, at least partially, by these other factors. Diabetes is a 
multifactorial disease; well established complex genetic and environmental interactions lead 
to increased susceptibility to its development and progression. Metabolic changes occurring 
in diabetes are also of multifactorial nature; diet and physical activity being the strongest 
independent predictors of the phenotype. Genetic polymorphisms explored in our study are 
most probably not major contributors to disease metabolic parameters in diabetic patients; 
however our results provide clear evidence for their association with HbA1c concentration.   
 
In conclusion, SUR-1 exon 16 and exon 31 polymorphisms are significantly associated with 
HbA1c concentration. 
Published reports on this issue are still contradictory and we were not able to confirm all of 
the previous findings. This is mostly due to heterogeneity of diabetes population and small 
genetic effect of single gene on polygenic traits. Further studies should investigate long-term 
follow-up of diabetics, and determine associations of these variants with therapeutic effect 
and chronic diabetes complications. 
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